What You Need To Know
In an effort to reduce the number of opioid-related overdose deaths, the FDA has approved the first generic naloxone nasal spray for use in a community setting by individuals without medical training.
The FDA is also taking these life-saving measures:
- Prioritizing its review of additional generic drug applications for naloxone
- Helping drug manufacturers pursue approval of an over-the-counter naloxone product
- Exploring ways to increase the availability of naloxone products within the community, including whether naloxone should be co-prescribed with all or some opioid prescriptions
Reminder: Opioid Training Deadline is June 30
The State Board of Medical Examiners’ deadline for mandatory opioid training is June 30, 2019. Hackensack’s May 16 CME event will help you meet this requirement.
For More Information
- Read the FDA’s announcement.
- Read these FAQs about New Jersey’s opioid prescribing law.
- Test your knowledge about New Jersey’s opioid prescribing law with this short quiz.